by PRI | Dec 6, 2022 | Microbiome Product Developer
Pedro Correa de Sampaio CEO Neobe is building a platform for the engineering of live biotherapeutics aimed at removing stromal barriers to immune infiltration in solid tumours, in order to enable existing immunotherapies in current non responding cancer patients....
by PRI | Dec 6, 2022 | Diagnostics
Etienne Formstecher CEO GMT Science develops routine, CE-marked microbiome analysis to improve the clinical management of chronic diseases....
by PRI | Oct 6, 2022 | News & Events
All PRI Members are invited to attend our first in-person Member Event since 2019! The Pharmabiotic Research Institute (PRI) is hosting its annual General Assembly & Member Event on 1 December 2022, in Rotterdam (NL). This Members-only meeting is our...
